

Put us to the test

Allergy

Simplify allergy diagnostics with selected, clinically relevant allergen profiles

Optimise allergy diagnostics with ImmunoCAP Specific IgE profiles* to support clinically guided, quantitative decision-making

Allergic diseases are common and often multifactorial.^{1,2} When allergy diagnostics are based on patient history and clinically relevant testing, they bring clarity from the very beginning and support more confident clinical decision-making.¹

ImmunoCAP Specific IgE profiles provide quantitative results that give clear insight into clinically relevant sensitisation. This supports more informed diagnosis and patient management.³

This clinically guided allergen profile approach supports targeted testing and helps avoid reliance on broad, non-specific multiplex panels.¹ A consistent approach to allergen selection using locally adapted, clinically relevant profiles helps identify sensitisation patterns, including polysensitised patients, and supports confident diagnosis, informed management, and well-defined referral decisions.^{1,3}

Laboratories play a **central role** in enabling clinically relevant allergen testing and **support primary care providers** in selecting appropriate first-line ImmunoCAP Specific IgE tests.

* ImmunoCAP Specific IgE profile is not a CE-marked product and is not placed on the market by Thermo Fisher Scientific. It is a laboratory-defined testing panel, consisting of individually CE-marked ImmunoCAP™ allergen products ordered separately by their official product names and article numbers.

Simplifying allergen selection



A structured testing approach supports greater alignment to allergen assessment across care settings.¹ When integrated through laboratory ordering systems, allergen profiles help guide primary care providers toward clinically relevant, first-line testing.³

ImmunoCAP™ Specific IgE tests deliver quantitative results that support informed clinical decision-making.³

Moving from individual case-by-case selection to a defined approach **helps laboratories and primary care providers** work more closely together and improves continuity of care.³

The value of early IgE testing in clinical practice

Structured, localised profiles include selected, clinically relevant allergens tailored to the local patient population and care setting.¹

When allergen selection follows a clinically guided approach, it can:

- Support targeted testing of clinically relevant allergens¹
- Deliver quantitative results to assess risk and severity⁴
- Enable confident detection of IgE-mediated sensitisation¹
- Detect clinically relevant sensitisation at low IgE levels⁷
- Enable follow-up testing to assess changes over time⁴

International clinical guidelines supports allergen selection based on patient history and relevant exposure patterns¹

Strengthening laboratory– clinician collaboration

When allergen profiles are integrated into laboratory ordering systems, they provide improved access to testing and support more consistent test selection.¹ In primary care, selecting clinically relevant IgE sensitisation tests can be challenging, and this approach helps laboratories guide primary care providers toward clinically relevant, appropriate testing.

Clinically guided allergen selection can:

- Simplify test ordering
- Encourage consistent request patterns³
- Reduce repeat or add-on testing
- Support earlier use of IgE testing³

Using ImmunoCAP Specific IgE profiles consistently over time supports reliable diagnosis, follow-up, and comparison of results. This reinforces the laboratory's role as a trusted diagnostic partner.⁷

Empowering confident decision-making in frontline care

**ImmunoCAP Specific IgE profiles can help
your primary care providers to:**

- Establish a clear starting point for first-line assessment¹
- Increase confidence in allergen selection¹
- Support clinically meaningful interpretation of results¹
- Enable informed management decisions¹
- Guide appropriate referral decisions when needed³

Interpreting specific IgE alongside total IgE and clinical context
can support a more complete diagnostic picture^{4,5}

A structured framework in allergy diagnostics. Adaptable locally.

Allergen sensitisation testing is based on a validated approach using selected, clinically relevant allergens representative of common sensitisation patterns in the local population.¹

This approach:

- Is adaptable to local epidemiology
- Aligns with regional reimbursement or coverage structures
- Reflects local clinical practice
- Preserves laboratory control and customisation

Profiles can be defined in collaboration with local allergists and laboratories, ensuring alignment with regional clinical needs and practice patterns.

ImmunoCAP™ testing is supported by a clinically relevant allergen portfolio, enabling laboratories to implement and tailor profiles to local patient populations.² These profiles are not fixed panels. They support a flexible, clinically guided approach to allergen sensitisation assessment across healthcare systems.¹



Structured. Clinically relevant. Laboratory enabled.

- Partner with us to integrate selected, clinically relevant allergen profiles within your ordering system.
- Align allergen selection with clinical guidance and regional needs.
- Support your requestors with a simplified and clinically relevant framework for allergy assessment.

References: 1. Santos AF, et al. EAACI guidelines on the diagnosis of IgE-mediated food allergy. *Allergy*. 2025;80(1):14-36. 2. Matricardi PM, et al. EAACI Molecular Allergology User's Guide. *Pediatr Allergy Immunol*. 2016;27 (Suppl 23):1-250. 3. Demoly P, et al. Pragmatic primary practice approach to using specific IgE in allergy diagnosis. *J Asthma Allergy*. 2022;15:1069-1080. 4. Platts-Mills T, et al. The role of allergens in asthma. *Am Fam Physician*. 2007;76:675-680. 5. Emanuel I. In vitro testing for allergy diagnosis. *Otolaryngol Clin North Am*. 2003;36:879-893. 6. Wallace DV, et al. Diagnosis and management of rhinitis: an updated practice parameter. *J Allergy Clin Immunol*. 2008;122(2 Suppl):S1-84. 7. Wise SK, et al. International Consensus Statement on Allergy and Rhinology. *Int Forum Allergy Rhinol*. 2023;13:293-859.

Learn more at thermofisher.com/immunocap

thermo scientific

Distributed by Abacus dx

1800 ABACUS (AUS) 0800 222 170 (NZ) | info@abacusdx.com | www.abacusdx.com

abacus dx